Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price reached a new 52-week low during trading on Monday . The company traded as low as $186.61 and last traded at $186.61, with a volume of 26 shares traded. The stock had previously closed at $187.73.
Genmab A/S Price Performance
The stock has a market cap of $13.72 billion, a price-to-earnings ratio of 19.96 and a beta of 1.04. The business has a fifty day moving average of $206.28 and a 200 day moving average of $230.43.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 17.73% and a net margin of 23.49%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
